Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

Wockhardt Ltd

WOCKPHARMA:NSI

Wockhardt Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,250.20
  • Today's Change95.65 / 8.28%
  • Shares traded339.65k
  • 1 Year change+451.84%
  • Beta2.0095
Data delayed at least 15 minutes, as of Nov 01 2024 13:51 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Wockhardt Limited is a research-based global pharmaceutical and biotech company. The Company is engaged in the pharmaceutical business. It focuses on the unmet need for antibacterial drugs that are effective against the menace of untreatable superbugs. It manufactures and supplies branded and generic finished formulations, as well as intermediate products like active pharmaceutical ingredients (APIs), worldwide. The Company’s products in India include EMROK, MERIWOK, REINVEXIN, ERLISO, METHYCOBAL TABLET, METHYCOBAL INJ, METHYCOBAL D, HAPID, PROXYFEN NANO GEL, LIVATIRA TABLET, LIVATIRA INJ, GABAWOK NT 100, GABAWOK NT 400, ETOBRIX 90, ETOBRIX TH4, ETOBRIX P, GLARZEN CARTRIDGE, GLARZEN DISPOPEN 2, ESOWOK D, TERITIDE, GLIMADAY, SITAWOK, GLARITUS, TRIMETADAY, MOPADAY, INOGLA, and ZINODAP. The Company has manufacturing and research facilities in India, United States of America and the United Kingdom and a manufacturing facility in Ireland.

  • Revenue in INR (TTM)28.93bn
  • Net income in INR-3.43bn
  • Incorporated1999
  • Employees2.39k
  • Location
    Wockhardt LtdWockhardt TowersBandra Kurla Complex, Bandra (East)MUMBAI 400051IndiaIND
  • Phone+91 2 226534444
  • Fax+91 2 226523905
  • Websitehttp://www.wockhardt.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Glenmark Life Sciences Ltd22.05bn4.24bn129.54bn2.01k30.675.1026.955.8834.4734.47179.44207.170.73041.462.7910,947,850.0014.0318.2816.6929.9954.9253.4019.2120.233.03380.550.006326.375.6420.830.84119.2169.11--
Marksans Pharma Ltd22.68bn3.34bn131.26bn2.00k39.29--31.665.797.377.3750.09--------11,339,960.00--14.62--18.5253.3950.5214.7114.03--32.19--6.1717.5616.8417.8032.6273.8664.38
Akums Drugs and Pharmaceuticals Ltd-100.00bn-100.00bn132.51bn7.39k------------------------------------------------14.32---104.25------
Granules India Ltd47.01bn4.92bn138.05bn4.12k28.07--19.642.9420.2920.29193.87--------11,403,970.00--10.68--16.1856.8948.8310.4711.82--6.95--8.96-0.12314.61-21.5411.386.388.45
Strides Pharma Science Ltd44.10bn1.77bn143.04bn3.07k80.936.2938.483.2419.2225.15479.84247.160.71551.503.5714,389,290.002.79-1.685.43-2.9760.1951.393.91-3.360.63551.520.5103--9.8313.2143.57---18.52-3.58
Caplin Point Laboratories Ltd17.58bn4.78bn154.71bn859.0032.48--28.648.8062.6762.67230.62--------20,462,630.00--19.83--22.8258.4153.3827.4325.39--1,525.59--9.0615.5021.1721.4820.9517.4717.84
Sanofi India Ltd23.83bn4.30bn156.48bn2.17k36.4122.8633.446.57186.62229.861,034.61297.261.672.7315.6010,960,440.0030.0822.4257.5530.2155.9555.5218.0421.030.8140435.860.0313135.492.920.573-2.859.64-10.3414.73
Eris Lifesciences Ltd24.98bn3.48bn180.09bn3.08k51.746.4928.917.2125.5725.57183.35203.740.45852.905.968,110,753.006.7313.428.3916.8077.0379.9814.6924.960.85993.410.4626--19.2315.392.576.1527.72--
Wockhardt Ltd28.93bn-3.43bn185.39bn2.39k------6.41-23.75-23.75199.60--------12,084,380.00---4.56---8.2958.6655.26-12.17-12.70--0.0764----5.55-4.7317.17---4.71--
Neuland Laboratories Ltd.16.35bn3.36bn187.40bn1.65k55.76--47.0311.46261.94261.941,274.50--------9,922,259.00--9.25--12.7153.3247.8120.5511.99--29.52--7.1330.8418.5183.5178.7617.8863.45
Astrazeneca Pharma India Ltd13.88bn958.59m190.62bn940.00198.86--171.8713.7438.3438.34555.18--------14,761,520.00--11.78--19.6248.5154.646.9110.27--121.25--25.6229.1712.2162.6624.29-10.46--
Concord Biotech Ltd10.38bn3.13bn191.48bn1.38k61.15--52.1818.4529.9329.9399.19--------7,537,496.00--------77.16--30.18----115.93----19.20--28.33------
Jubilant Pharmova Ltd69.20bn5.93bn191.94bn995.0032.413.2319.862.7737.3837.38436.41375.040.59341.758.1569,544,720.005.052.966.013.5568.5068.478.515.131.202.510.34224.736.70-5.95226.43-33.086.482.13
Alembic Pharmaceuticals Ltd63.04bn6.30bn221.89bn14.86k35.23--24.513.5232.0432.04320.63--------4,242,974.00--10.72--14.2573.1065.989.9912.47--12.52--28.2910.199.6280.071.05-15.5914.87
Pfizer Ltd22.38bn6.18bn233.22bn1.72k37.756.2234.3610.42135.06135.06489.19819.900.52881.8311.1613,004,360.0014.6014.2217.0517.7165.0061.3727.6124.054.3046.210.026782.67-9.551.05-11.645.1433.359.24
Natco Pharma Ltd.42.21bn16.37bn251.28bn4.02k15.35--13.785.9591.3791.37235.68--------10,510,210.00--12.33--14.2583.4073.0538.7725.16--91.13--18.9647.7213.8194.0916.59-4.7114.87
Data as of Nov 01 2024. Currency figures normalised to Wockhardt Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

6.06%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 20242.81m1.83%
ICICI Prudential Asset Management Co. Ltd.as of 30 Sep 20241.95m1.27%
Dimensional Fund Advisors LPas of 03 Oct 20241.09m0.71%
Samco Asset Management Pvt. Ltd.as of 30 Sep 2024801.53k0.52%
BlackRock Fund Advisorsas of 03 Oct 2024770.79k0.50%
Invesco Asset Management (India) Pvt Ltd.as of 30 Sep 2024486.36k0.32%
Mirae Asset Investment Managers (India) Pvt Ltd.as of 30 Sep 2024483.56k0.32%
Norges Bank Investment Managementas of 30 Jun 2024350.81k0.23%
SSgA Funds Management, Inc.as of 03 Oct 2024292.06k0.19%
HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 30 Sep 2024259.21k0.17%
More ▼
Data from 30 Jun 2024 - 15 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.